CD79A and shigellosis: In an immunoprofiling study with sera from the EcSf2a-2 efficacy trial, pre-challenge IpaB-specific IgG+ and IgA+ levels and Fcγ receptor binding negatively correlated with all measured shigellosis symptoms following challenge [15].